Sol-Gel Technologies (SLGL) Total Non-Current Liabilities (2016 - 2026)
Sol-Gel Technologies (SLGL) reported Total Non-Current Liabilities of $831000.0 for Q1 2026, down 64.15% year-over-year from $2.3 million in Q1 2025, and down 11.12% quarter-over-quarter from $935000.0 in Q4 2025.
Sol-Gel Technologies (SLGL) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 11 years of Total Non-Current Liabilities data on file, last reported at $831000.0 in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $831000.0, down 64.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $831000.0 (down 64.15% YoY), and the FY2025 annual result was $935000.0, down 45.35% from the prior year.
- Total Non-Current Liabilities eased to $831000.0 in Q1 2026 per SLGL's latest filing, from $935000.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $2.5 million in Q2 2025 and troughed at $831000.0 in Q1 2026.
- A 5-year average of $1.7 million and a median of $1.7 million in 2022 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities jumped 95.3% in 2023, then tumbled 64.15% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $1.1 million in 2022, then jumped by 95.3% to $2.1 million in 2023, then dropped by 19.33% to $1.7 million in 2024, then sank by 45.35% to $935000.0 in 2025, then decreased by 11.12% to $831000.0 in 2026.
- Business Quant data shows SLGL's Total Non-Current Liabilities at $831000.0 in Q1 2026, $935000.0 in Q4 2025, and $2.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | 831,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 831,000.00 |
| Dec 31, 2025 | 935,000.00 |
| Sep 30, 2025 | 2.42 Mn |
| Jun 30, 2025 | 2.47 Mn |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | 1.71 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Mar 31, 2024 | 2.04 Mn |
| Dec 31, 2023 | 2.12 Mn |
| Sep 30, 2023 | 2.23 Mn |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 1.09 Mn |
| Sep 30, 2022 | 1.22 Mn |
| Jun 30, 2022 | 1.41 Mn |
| Mar 31, 2022 | 1.72 Mn |
| Dec 31, 2021 | 1.90 Mn |
| Sep 30, 2021 | 1.86 Mn |
| Jun 30, 2021 | 2.00 Mn |